Pegfilgrastim biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 25 Nov 2021
Price :
$50 *
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Radioprotectives; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 24 Feb 2016 No development reported - Registered for Neutropenia (Parenteral)
- 24 Feb 2016 No development reported for Neutropenia in European Union (Parenteral)
- 14 Aug 2013 Investigation in Neutropenia in European Union (Parenteral)